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Abstract The efficacyoftelithromycinhasbeen assessedin six Phase III studiesinvolvingadultswithmild tomoderate
community-acquiredpneumonia (CAP) with a degree of severitycompatiblewith oral therapy.
Patients received telithromycin 800mg once daily for 7^10 days in three open-label studies (n=870) and three rando-
mized, double-blind, comparator-controlled studies (n=503). Comparator antibacterials were amoxicillin 1000mg
three-timesdaily, clarithromycin 500mg twice dailyandtrovafloxacin 200mgonce daily. Clinical andbacteriologicalout-
comeswere assessed 7^14 dayspost-therapy.
Among telithromycin-treated patients, per-protocol clinical cure rateswere 93.1and 91.0% for the open-label and com-
parative studies, respectively.Telithromycin treatment was as effective as the comparator agents.High eradication and
clinical cure rateswere observed for infections caused bykeypathogens: Streptococcus pneumoniae including isolates re-
sistant to penicillin G and/or erythromycin A (95.4%), Haemophilus influenzae (89.5%) and Moraxella catarrhalis (90%).
Telithromycin was also highly effective in patients with infections caused by atypical and/or intracellular pathogens and
those at increasedriskofmorbidity.Telithromycinwasgenerally well tolerated.
Telithromycin 800 mg once daily for 7^10 days offers a convenient andwell-tolerated first-line oral therapy for the em-
pirical treatmentofmild tomoderate CAP.r2003 Elsevier Science Ltd.Allrights reserved.
doi:10.1053/rmed.2003.1492, available online athttp://www.sciencedirect.com
Keywords Telithromycin (HMR 3647); ketolide; community-acquired pneumonia (CAP); antibacterial resistance; Streptococcus
pneumoniae.INTRODUCTION
Community-acquired pneumonia (CAP) is a signi¢cant
cause of morbidity and mortality worldwide. In the
USA, there are up to 3 million cases of CAP each year,
accounting for approximately 10 million physician visits,
500 000 hospitalizations, and 45 000 deaths (1,2). Simi-
larly, in Germany, severe CAP accounts for approxi-
mately 10% of hospitalized patients (3), and in the
United Kingdom,mortality rates amonghospitalizedpa-
tients range from 6^12% (4).
The majority of CAP cases are caused by bacterial in-
fections, with Streptococcus pneumoniae,Haemophilus in-
£uenzae and Moraxella catarrhalis being the three most
frequent typical bacterial pathogens isolated. The num-Received 22 July 2002, accepted in revised form 4 November 2002.
Correspondence should be addressed to: Professor Lars Hagberg,
Sahlgrenska University Hospital, Department of Infectious Diseases,
41685 G˛teborg, Sweden Fax: +46 31847 813;
E-mail address: lars.hagberg@medfak.gu.seber of cases caused by M. catarrhalis infections is much
lower than that causedby S. pneumoniae orH. in£uenzae.
S. pneumoniae is the most frequently isolated pathogen
and is responsible for 20^40% of all cases of CAP where
a speci¢c pathogen is identi¢ed (4,5). Additionally, atypi-
cal and/or intracellular pathogens, such as Mycoplasma
pneumoniae, Chlamydophila (Chlamydia) pneumoniae and
Legionella pneumophila, have been reported to account
for a signi¢cant number of cases of CAP (6), andmay of-
ten be present in addition to a typical pathogen (4).CAP
caused by L. pneumophila is often associated with more
severe infection and is linkedwith a high riskofmortality
(15%) (7^9).
Despite the development of better diagnostic techni-
ques, up to 50% of all reported cases of CAPwill have no
pathogen identi¢ed and initial treatment is of necessity
largely empirical (2,7,10).There is an increasing trend for
outpatient therapy for patients that would previously
have been hospitalized.This has been encouraged by the
development of the Fine criteria to identify patients at
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FIG. 1. Chemical structure of telithromycin indicating the key
features thatdi¡erentiate it fromthemacrolides.
626 RESPIRATORYMEDICINElow risk of death and is supported by the results of sev-
eral studies that demonstrate that many patients with
CAP can be adequately treated on an ambulatory basis
(11^13). Current treatment options for CAP include b-
lactams, macrolides, £uoroquinolones and doxycycline.
In recent years, the choices for empirical therapy have
become limited by the emergence and spread of patho-
gens that are resistant to many of the currently used
¢rst-line antibacterials, a problem that is steadily in-
creasing worldwide. Prospective Resistant Organism
Tracking and Epidemiology for the KetolideTelithromy-
cin (PROTEKT) is an international surveillance study
which documents the antibacterial susceptibility of
pathogens isolated from patients with community-ac-
quiredrespiratory tract infections (RTIs).Preliminaryre-
sults for S. pneumoniae isolates worldwide con¢rm the
increasing problem of resistance to many antibacterial
agents including penicillin (minimum inhibitory concen-
tration [MIC]Z 2.0mgl1; 42.3%) and erythromycin A
(MICZ1.0mgl1; 42.7%) (14). However, there is regional
variation in the incidence of resistance. In Europe, for ex-
ample, penicillin resistance rates areo10% in a number
of countries, including Sweden, Germany, The Nether-
lands and the UK (15,16). ErythromycinA resistance is of
particular concern as it can confer cross-resistance to all
macrolides, lincosamides and streptogramin group B
(MLSB) antibacterials.Many penicillin-resistant pneumo-
cocci are also becoming increasingly resistant to the
newer macrolides and £uoroquinolones (17^20).The de-
velopment of resistance is closely linked with regional
prescription and usage patterns for macrolides, penicil-
lins and £uoroquinolones. (17,21^23). In the case of
macrolides, resistance in the USAwas reported to dou-
ble in the 5 years between1995 and1999 and is now gen-
erally420% (23).
Failure to eradicate bacterial infections because of in-
creased resistance may result in poor clinical outcomes
(24^27). This highlights the need for new antibacterial
treatments that are highly e¡ective against resistant
pathogens and that have a low propensity to select for
or induce resistance or cross-resistance, yet can still be
used empirically.
Telithromycin is the ¢rst compound in a new class of
antibacterialsFthe ketolidesFto be approved for clini-
cal use.Ketolides are a novel addition to the MLSB family
of antibacterials, but have several important structural
and functional di¡erences. In telithromycin, the C3 cladi-
nose sugar of macrolides, previously thought to be es-
sential for antibacterial activity, has been substituted
with a keto group (Fig.1).The keto group confers excel-
lent acid stability (28), and has also been shown to pre-
vent induction of MLSB resistance by ketolides in vitro
(29,30). Furthermore, the addition of a C11,12-carbamate
side chain enhances both antibacterial activity and bind-
ing toMLSB -resistant ribosomes, whichmay explain tel-
ithromycin’s ability to overcomeMLSB resistance (31^33).Telithromycin acts at two levels: by inhibiting the as-
sembly of ribosomes (as do macrolides) and by inhibiting
translation through interactions with domains II and Vof
the 23S rRNA. In contrast to macrolides, telithromycin
interacts strongly with nucleotide A752 in domain II
and this appears to account for its ability to bind to
MLSB-resistant ribosomes (31^35). Thus, telithromycin
has been speci¢cally designed to preserve antibacterial
activity while circumventing selection of resistance and
hence to provide optimal therapy for CAP and other
upper and lower community-acquired RTIs (36).
Telithromycin provides a well-balanced spectrum of
activity against the key respiratory pathogens (Table 1)
(37^42). In vitro, telithromycin is 2- to 4-foldmorepotent
than clarithromycin or azithromycin against susceptible
S. pneumoniae, and at least 10-fold more potent than
these agents against S. pneumoniae isolates with inter-
mediate or full resistance to b-lactams or erythromycin
A (37). Telithromycin’s activity against erythromycin A-
resistantpneumococci notonly includesmef-positive (ef-
£ux) isolates, but also extends to isolates showing indu-
cible and constitutive MLSB (erm) resistance (43). In
addition, many isolates that havebeen shown to be resis-
tant to macrolides through mutations of the drug^ribo-
some binding site remain susceptible to telithromycin
(44). Against H. in£uenzae, telithromycin demonstrates
a level of activity comparable with that of the newer
macrolides azithromycin and clarithromycin (38). Teli-
thromycin is highly active against atypical respiratory
pathogens such as M. pneumoniae, and the intracellular
pathogens C. pneumoniae and L. pneumophila (39^
41,45,46). Additionally, telithromycin possesses a low po-
tential to select for resistance or induce cross-resistance
to other MLSB antibacterials (47,48).
Telithromycin exhibits ideal coverage for bacterial
pathogens causing community-acquired RTIs. This
TABLE 1. Summary of the in vitro antibacterial activity of telithromycin against causative pathogens of community-acquired
pneumonia
MIC (mgl1)
Pathogen MIC50 MIC90 Range Reference
Streptococcuspneumoniae
Ery-S 0.016 0.03 r0.004^0.06 Pankuch et al. (37)
Ery-R 0.06 0.25 0.008^1.0 Pankuch et al. (37)
Pen-S 0.016 0.03 r0.004^0.125 Pankuch et al. (37)
Pen-R 0.03 0.25 r0.004^1.0 Pankuch et al. (37)
Haemophilus in£uenzae 2.0 4.0 0.03^8.0 Biedenbach et al. (38)
Moraxella catarrhalis 0.06 0.12 r0.015^0.25 Biedenbach et al. (38)
Mycoplasma pneumoniae r0.015 r0.015 r0.015 Bebear et al. (39)
Chlamydophila pneumoniae 0.0625 0.25 0.031^2.0 Roblin and Hammerschlag (40)
Legionella pneumophila 0.015 0.03 r0.004^0.12 Schulin et al. (41)
Ery-S/Ery-R: erythromycin A susceptible/resistant; Pen-S/Pen-R: penicillin G susceptible/resistant. Penicillin G susceptible
MICr 0.06mgl1; penicillin Gresistant MICZ 2.0mgl1; erythromycin A susceptible MICr 0.25mgl1; erythromycin A
resistant MICZ1.0mgl1.
TELITHROMYCININTHE TREATMENTOFCOMMUNITY-ACQUIREDPNEUMONIA 627spectrum of activity encompasses common and atypical/
intracellular pathogens including resistant strains, mak-
ing it an attractive new option for empirical treatment
ofmild tomoderateCAP andother community-acquired
upper and lower RTIs.
Telithromycin is administered orally at a recom-
mended once-daily dosage of 800mg (2400mg ta-
blets). At this dosage, it rapidly reaches maximal plasma
concentrations and penetrates into bronchopulmonary
tissues and £uids. Pharmacokinetic/pharmacodynamic
studies in animals and humans have demonstrated
that the e⁄cacy of telithromycin in vivo is concentration
dependent and correlates with its area under the con-
centration^time curve AUC/MIC ratio (49,50). Concen-
trations at the site of infection aremaintained above the
MIC for most respiratory pathogens for up to 24h after
dosing (51,52). In contrast to azithromycin, telithromycin
also maintains e¡ective concentrations in plasma
throughout the dosing period (53,54).
This paper reviews the clinical andbacteriological e⁄-
cacy of telithromycin in the treatment of 1373 patients
with mild to moderate CAP in six Phase III, multicentre,
multinational clinical trials (conducted between Febru-
ary1998 and September 2000): three double-blind, ran-
domized, controlled comparative studies (n=573) and
three open-label studies (n=870);Table 2) (55^60).
METHODS
Enrolment criteria for patients in all six trials included a
radiologically con¢rmed diagnosis of CAP and the pre-
sence of at least two signs and symptoms of CAP (cough,
production of purulent sputum, auscultatory ¢ndings,
dyspnoea, fever, white blood cell count410 000mm3orGram-positive diplococci in sputum).Both in- and out-
patientswere includedin the studiesbut those for whom
oral medication was not appropriate were excluded, as
were patients who had received treatment with other
antibacterials in the last 7 days.
Patients received two 400mg telithromycin tablets
(total 800mg) orally once daily for 7^10 days or a com-
parator agent (Table 2).The comparatordrugs chosen in-
cluded high-dose amoxicillin and clarithromycin, both
recommended as ¢rst-line treatments in international
guidelines (4,61,62), and trova£oxacin. At the time of the
studies, trova£oxacinwas selectedbecause itwas one of
the most potent £uoroquinolones available. Patients
were assessed on separate visits: pretherapy/entry (day
1), on-therapy (days 3^5), end of therapy (days 11^13),
post-therapy/test of cure (TOC) (days 17^24) and late
post-therapy (days 31^45). The post-therapy/TOC visit
was designed to capture early relapses as failures and
thus provide a vigorous test of e⁄cacy.
Patients with a con¢rmed diagnosis of CAP receiving
at least one dose of study medication were included in
themodi¢ed intent-to-treat (mITT) population. Patients
with no major protocol deviations following randomiza-
tion were included in the per-protocol analysis. Clinical
and bacteriological outcomes were determined at the
post-therapy/TOCvisit.
The clinical outcome assessmentwas based on clinical
signs, symptoms and X-ray ¢ndings and was classi¢ed as
cure, failure or intermediate. Cure was further distin-
guished as either returning to the preinfection state or
with improved symptoms. Subjects with residual symp-
toms requiring further antibacterial treatment were
classi¢ed as failure.
Pathogens isolated frompretherapyblood and sputum
samples were considered causative for CAP. Isolates
TABLE 2. Summaryof Phase III clinical trials oftelithromycin inpatientswith community-acquiredpneumonia
Telithromycin Comparator
Studyno. Dosage
(duration)
No. of
patients*
Drug Dosage
(duration)
No. of
patientsa
Reference
Controlled studies
3001 800mgqd (10 days) 199 Amoxicillin 1000mg tid (10 days) 205 Hagberg et al. (55)
3006 800mgqd (10 days) 204 Clarithromycin 500mgbid (10 days) 212 Tellier et al. (56)
3009 800mgqd (7^10 days) 100 Trova£oxacin 200mgqd (7^10 days) 104 Pullman et al. (57)
Total 503
Open-label studies
3000 800mgqd (7^10days) 240 F F F Carbon et al. (58)
3099 800mgqd (7^10days) 212 F F F van Rensburg et al. (59)
3010 800mgqd (7days) 418 F F F Fogarty et al. (60)
Total 870
*Numberofpatientswith a con¢rmeddiagnosiswhoreceivedatleastonedoseof studymedication (modi¢edintent-to-treat
population). bid: twice daily; qd: once daily; tid: three-times daily.
TABLE 3. Clinical cure rates at the post-therapy test of cure visit for patients with community-acquired pneumonia adminis-
tered telithromycin 800mgonce-daily for 7^10 days or comparatordrug
Studyno. Telithromycin n/N (%) Comparator n/N (%) Di¡erence (%) (95% CI)
Per-protocol population
3001 141/149 (94.6) 137/152 (90.1) 4.5 (2.1,11.1)
3006 143/162 (88.3) 138/156 (88.5) 0.2 (7.9; 7.5)
3009 72/80 (90.0) 81/86 (94.2) 4.2 (13.6, 5.2)
All controlled studies 356/391 (91.0) 356/394 (90.4) 0.6 (3.6, 5.0)
3000 183/197 (92.9) F F
3099 175/187 (93.6) F F
3010 332/357 (93.0) F F
All open-label studies 690/741 (93.1) F F
Modi¢ed intent-to-treat population
3001 171/199 (85.9) 161/205 (78.5) 7.4 (0.5,15.3)
3006 161/204 (78.9) 171/212 (80.7) 1.8 (9.9,6.5)
3009 82/100 (82.0) 89/104 (85.6) 3.6 (14.7,7.5)
All controlled studies 414/503 (82.3) 421/521 (80.8) 1.5 (3.4,6.4)
3000 191/240 (79.6) F F
3099 182/212 (85.8) F F
3010 357/418 (85.4) F F
All open-label studies 730/870 (83.9) F F
CI: con¢dence interval.
628 RESPIRATORYMEDICINEwere tested for their susceptibility to penicillin G, ery-
thromycin A and telithromycin by National Committee
for Clinical Laboratory Standards (NCCLS) MIC testing
at two central laboratories. Infections due to atypical
pathogens were diagnosed by serology and/or polymer-
ase chain reaction (PCR) analysis of sputum samples fol-
lowing stringent criteria (based on US Food and Drug
Administration recommendations). Patients were con-
sidered to have an atypical infection if they had anegative
culture for typical pathogens and met the following cri-
teria:C. pneumoniaeFpositive culture, 4-fold increase inmicroimmuno£uorescence IgG titres or a single IgM titre
Z 1/32 by microimmuno£uorescence with a positive
PCR result;M. pneumoniaeFpositive culture, 4-fold in-
crease in serum IgG or single IgM titreZ 1/16 by micro-
immuno£uorescence with a positive PCR result; L.
pneumophilaFpositive culture, 4-fold increase in serum
IgGor IgM titre or a positiveurine antigen for L. pneumo-
phila serogroup1.
Satisfactory bacteriological outcome was de¢ned as
documented eradication of the causative pathogen or
clinical improvement to the extent that a follow-up
FIG. 2. Distribution of common causative pathogens for com-
munity-acquired pneumonia in the per-protocol population
across all studies.
TABLE 4. Minimum inhibitory concentrations (MICs) of
telithromycin for key causative pathogens* isolated from
patients with community-acquired pneumonia (per pro-
tocol)
Pathogen/MIC (mgl1) No. of patients
Streptococcus pneumoniae (n=153)
0.004 2
0.008 38
0.016b 81
0.03 21
0.06 3
0.12 2
0.25 1
0.5 2
1.0 3
Blood isolates (n=38)
0.008 6
0.016b 23
0.03 4
0.06 2
0.12 1
1.0 2
Haemophilus in£uenzae (n=97)
0.002 1
0.12 1
0.25 1
0.5 1
1 21
2 38
4 29
8 5
Moraxella catarrhalis (n=25)
0.06 10
0.12 15
Staphylococcus aureus (n=18)
0.06 3
0.12 12
0.25 3
*Respiratory and/or blood isolates.
w0.015 and 0.016mgl1pooled.
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therefore, presumed to be eradicated. Conversely, pre-
sumed bacterial failure occurred when, by de¢nition,
clinical failure was the outcome. While this criterion
mayoverstate truemicrobiological failure, itwas applied
consistently to all study arms.
Safety assessments were carried out on all patients
who had received at least one dose of studymedication,
andwho had at least one post-baseline clinical or labora-
tory assessment. All adverse events, whether reported
spontaneously by the patients or observed by the inves-
tigator, were recorded. In addition, laboratory ¢ndings
or results of other diagnostic procedures (including 12-
lead electrocardiograms [ECG]) considered to be clini-
cally relevant were reported as adverse events.
RESULTSANDDISCUSSION
Clinical and bacteriological e⁄cacy
Per-protocol analysis of clinical cure rates demonstrated
that a 7- to10-day course of telithromycin 800mg (once
daily) was at least as e¡ective as standard antibacterials
(Table 3): amoxicillin 1000mg three-times daily for 10
days; clarithromycin 500mg twice daily for10 days; tro-
va£oxacin 200mg once daily for 7^10 days (55^57). Teli-
thromycin achieved a high overall clinical cure rate in the
comparator studies of 91.0%.
Clinical cure rates for telithromycin were similar in
the open-label studies (Table 3) (58^60).The overall clin-
ical cure rate in the open-label studies was 93.1%.
The results for clinical outcome in the mITT popula-
tion con¢rmed the per-protocol analysis, demonstrating
equivalence to comparator agents (Table 3). The clinicalcure rates in this population supported the good clinical
e⁄cacy demonstrated in the per-protocol population,
but were slightly lower due to the inclusion of patients
with indeterminate outcomes.
Consistent with the high clinical cure rate, 90.2 and
90.8% of telithromycin-treated patients achieved a satis-
factory bacteriological outcome in the controlled and
open-label studies, respectively. As expected, S. pneumo-
niae and H. in£uenzaewere themost commonly isolated
pathogens (Fig. 2). The MICs of telithromycin for key
causativepathogens isolated in these studies are detailed
inTable 4. All isolates of S. pneumoniae were susceptible
to telithromycin at a tentative susceptibility breakpoint
ofr 1.0mgl1 (mode 0.016mgl1), and all H. in£uenzae
TABLE 5. Bacteriological eradication and clinical cure rates, bypathogen, atthe post-therapy/testof cure visit after 7^10 days’
treatmentwithtelithromycin 800mgonce daily (per-protocolpopulation)
Causative pathogen Bacteriological eradication n/N (%) Clinical cure n/N (%)
Streptococcus pneumoniae 166/174 (95.4) 165/174 (94.8)
Haemophilus in£uenzae 94/105 (89.5) 95/105 (90.5)
Moraxella catarrhalis 27/30 (90.0) 26/30 (86.7)
Staphylococcus aureus 15/19 (78.9) 15/19 (78.9)
Other 98/114 (86.0) 102/114 (89.5)
Total (allpathogens) 400/442 (90.5) 403/442 (91.2)
TABLE 6. Clinicalcure andbacteriologicaleradicationrates atthepost-therapy/testofcurevisit after 7^10 days’treatmentwith
telithromycin 800mg once daily in patients infectedwith penicillin G- and/or erythromycin A-resistant Streptococcus pneumo-
niae (per-protocolpopulation)
Resistance pro¢le Clinical cure n/N (%) Bacteriological eradication n/N (%)
Single-pathogen infections
All isolates 122/127 (96.1) 122/127 (96.1)
Pen-R 8/9 (88.9) 8/9 (88.9)
Ery-R 8/9 (88.9) 8/9 (88.9)
Pen-Ror Ery-R 13/14 (92.9) 13/14 (92.9)
Single- andmixed-pathogen infections
All isolates 165/174 (94.8) 165/174 (94.8)
Pen-R 13/16 (81.3) 13/16 (81.3)
Ery-R 13/16 (81.3) 13/16 (81.3)
Pen-Ror Ery-R 20/23 (87.0) 20/23 (87.0)
Pen-R: penicillin Gresistant (MICZ 2.0mgl1);Ery-R: erythromycin Aresistant (MICZ1.0mgl1).
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FIG. 3. Clinical cure rates at the post-therapy/test of cure visit
after 7^10 days’treatment with telithromycin 800mg once daily
and comparator antibacterials in patients with community-ac-
quired pneumonia caused by atypical/intracellular pathogens
(per-protocolpatients).
630 RESPIRATORYMEDICINEisolates, irrespective of b-lactamase production, were
inhibited byr 8mgl1telithromycin (mode 2mgl1).
The pooled analysis of bacteriological eradication and
clinical cure rates by pathogen in telithromycin-treated
patients is summarized inTable 5. Per-protocol popula-
tions with causative agents identi¢ed at pretreatment
showedhigh eradication rates for common pathogens.
High clinical cure and eradication rateswere observed
for patients with infections caused by S. pneumoniae
(94.8% clinical cure, 95.4% eradication). Patients infected
with penicillin G- and/ormacrolide (erythromycin A)-re-
sistant S. pneumoniae had comparable rates of clinical
cure and bacterial eradication (Table 6). The macrolide
(erythromycin A)-resistant isolates included both mef
and erm isolates (MIC range 4 to4512mgl1).
The rates of clinical cure and bacterial eradication
were also high for theGram-negative pathogensH. in£u-
enzae (89.5% clinical cure, 90.5% eradication) andM. cat-
arrhalis (90.0% clinical cure, 86.7% eradication). All of the
5 patients with infections caused by H. in£uenzae strains
with telithromycin MICs of 8mgl1achieved clinical cure
with corresponding bacterial eradication. Fourteen pa-
tients with H. in£uenzae infections were infected with
b-lactamase producing strains of this pathogen.Of these
14 patients, 12 (85.7%) achieved both bacterial eradica-tion and clinical cure at thepost-therapy/TOCvisit, com-
parable with the overall eradication and clinical cure
rates forH. in£uenzae infected patients.
Clinical cure andbacterial eradication rates in patients
with staphylococcal pneumonia were also good (78.9%
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FIG. 4. Clinical cure rates at the post-therapy/test of cure visit
after 7^10 days’treatment with telithromycin 800mg once daily
in at-risk patients with community-acquired pneumonia (per-
protocolpatients).
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caused by S. aureus is often severe, frequently associated
with viral infection and di⁄cult to treat (63).
Telithromycin showed excellent clinical e⁄cacy
against infections caused by the atypical and/or intracel-
lular pathogens C. pneumoniae, M. pneumoniae and L.
pneumophila, with cure rates of 94.1, 96.8 and 100%, re-
spectively (Fig. 3).
Certain patients with CAP are at increased risk of
morbidity and mortality, i.e. the elderly (Z 65 years of
age) and those with more severe disease (e.g. Fine score
class ZIII [10]) or with pneumococcal bacteraemia.
Once-dailyoral therapy with telithromycinwashighly ef-
fective in these at-risk patientgroups (Fig.4).Clinical out-
comes for these patient groups were similar to that of
the overall population.For thosepatientswith bacterae-
mia who were reported as clinical failures, only one was
a documented bacteriological failure. Of those patients
in the per-protocol population, 20% were hospitalized
on admission to the study. Clinical cure rates for non-
hospitalized and hospitalized patients were 92.6 and
92.4%, respectively. Telithromycin may therefore be an
e¡ective treatment for those CAP patients admitted to
hospital for whom oral therapy is appropriate.
Tolerability and safety of telithromycin in the
treatment of patientswith CAP
The tolerability and safetyof telithromycin havebeen es-
tablished in three comparative Phase III clinical trials in
CAP patients.
Telithromycin treatment was generally well tolerated
andwas associatedwith a low rate of treatment discon-
tinuation (4.9%). Most adverse events were of mild to
moderate intensity.Themost frequent treatment-related
events were diarrhoea (13.1%), nausea (8.0%), vomiting
(2.3%) and dizziness (2.1%). Although telithromycin
treatmentwas associatedwith a higher incidence of diar-
rhoea vs. individual comparatorsF5.9% (amoxicillin), 6.4% (trova£oxacin), 7.2% (clarithromycin)Fmost instances
were mild and no telithromycin-treated patients in the
comparative studies discontinued treatment as a result
of diarrhoea.
There was no evidence that telithromycin is asso-
ciated with an excess risk of hepatic e¡ects.The e¡ects
of telithromycin on liver function tests and the adverse-
events pro¢le were similar to that of the macrolide
group.
There was no signi¢cant di¡erence in ECG e¡ects or
in the incidence of cardiovascular adverse events when
telithromycin was compared with both macrolide and
nonmacrolide antibacterials. Telithromycin was compar-
able to clarithromycinwith respect to QTc changes.
The safety pro¢le of telithromycin in the open-label
studieswas similar to that in the comparative studies de-
scribed above. In one of the open-label studies (58), the
incidence of elevated alanine transaminase (ALT) levels
(11.3%) was higher than that observed in any of the other
CAP studies.Themajority of the a¡ectedpatients in this
study had ALT levels above the normal range at the pre-
therapy visit.Thus, thehigher incidence of clinicallynote-
worthy abnormal laboratory values for ALT levels
observed in this study may be accounted for by di¡er-
ences in the disease characteristics of this study popula-
tion. These patients had higher baseline morbidity,
demonstrated by the 74% of patients hospitalized on en-
try to this study compared with 0^35.7% of patients in
other studies.
CONCLUSIONS
At a convenientdosage of 800mgonce daily for 7^10days
in the treatment ofmild tomoderate CAP, telithromycin
waswell tolerated and achievedhigh rates of clinical cure
and satisfactory bacteriological outcome vs. a broad
range of comparative agents.This favourable pro¢le ex-
tends to patients with mild to moderate CAP due to
both typical and atypical/intracellular pathogens and
even to those patients with infection due to penicillin-
and/or macrolide-resistant S. pneumoniae, and b-lacta-
mase producing strains ofH. in£uenzae.
Telithromycin provides excellent e⁄cacy in subgroups
of vulnerable patients who are at increased risk of mor-
bidity and mortality, such as the elderly and those with
more severe infection (Fine score class Z III or those
with pneumococcal bacteraemia). Interestingly, there is
a growing awareness that treatment with oral antibac-
terials is often appropriate for hospitalized patients with
non-severe CAP (4).
On the basis of these ¢ndings, telithromycin repre-
sents a promising new oral antibacterial agent for ¢rst-
line empirical therapy ofmild tomoderate CAP in all pa-
tient groups.
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